Trust Company of Virginia maintained its stake in Walgreens Boots Alliance Inc (NASDAQ:WBA) during the fourth quarter, according to its most recent disclosure with the SEC. The hedge fund owned 13,974 shares of the pharmacy operator’s stock at the end of the fourth quarter. Trust Company of Virginia’s holdings in Walgreens Boots Alliance were worth $1,190,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Janus Capital Management boosted its stake in Walgreens Boots Alliance by 35.5% in the third quarter. Janus Capital Management now owns 1,324,869 shares of the pharmacy operator’s stock worth $110,097,000 after buying an additional 346,993 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft bought a new stake in shares of Walgreens Boots Alliance during the third quarter valued at about $19,336,000. MUFG Americas boosted its stake in shares of Walgreens Boots Alliance by 10.0% in the third quarter. MUFG Americas now owns 98,191 shares of the pharmacy operator’s stock valued at $8,160,000 after buying an additional 8,897 shares in the last quarter. Natixis Asset Management bought a new stake in shares of Walgreens Boots Alliance during the third quarter valued at about $423,000. Finally, ICON Advisers boosted its stake in shares of Walgreens Boots Alliance by 70.4% in the third quarter. ICON Advisers now owns 12,100 shares of the pharmacy operator’s stock valued at $1,006,000 after buying an additional 5,000 shares in the last quarter.

Shares of Walgreens Boots Alliance Inc (NASDAQ:WBA) traded up 2.36% during trading on Friday, hitting $80.84. 3,449,158 shares of the company’s stock were exchanged. The company has a 50-day moving average of $82.87 and a 200-day moving average of $87.02. The company has a market cap of $87.21 billion and a P/E ratio of 19.68. Walgreens Boots Alliance Inc has a 12-month low of $73.00 and a 12-month high of $97.30.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its earnings results on Thursday, January 7th. The pharmacy operator reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.07. The firm earned $29 billion during the quarter, compared to analyst estimates of $29.24 billion. The company’s quarterly revenue was up 48.5% on a year-over-year basis. On average, equities analysts expect that Walgreens Boots Alliance Inc will post $4.48 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on WBA shares. Vetr cut shares of Walgreens Boots Alliance from a “strong-buy” rating to a “buy” rating and set a $93.97 target price on the stock. in a report on Wednesday, October 7th. Cowen and Company decreased their price target on shares of Walgreens Boots Alliance from $104.00 to $102.00 in a research report on Wednesday, October 21st. Jefferies Group increased their price target on shares of Walgreens Boots Alliance from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Wednesday, October 28th. RBC Capital upgraded shares of Walgreens Boots Alliance from a “hold” rating to a “buy” rating and increased their price target for the stock from $98.00 to $103.00 in a research report on Wednesday, October 28th. Finally, Barclays decreased their price target on shares of Walgreens Boots Alliance from $86.00 to $81.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Walgreens Boots Alliance has a consensus rating of “Buy” and a consensus price target of $96.86.

In other Walgreens Boots Alliance news, Director William C. Foote sold 3,500 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $88.36, for a total transaction of $309,260.00. Following the completion of the transaction, the director now directly owns 30,823 shares in the company, valued at $2,723,520.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barry Rosenstein sold 1,452,470 shares of the company’s stock in a transaction on Friday, November 20th. The stock was sold at an average price of $82.37, for a total transaction of $119,639,953.90. The disclosure for this sale can be found here.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand). In addition, the Company has investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Company Limited. The Company operates in around 25 countries, which include the wholesale and distribution network with over 340 distribution centers and more than 180,000 pharmacies, health centers and hospitals in 19 countries.

12 Month Chart for NASDAQ:WBA

Receive News & Ratings for Walgreens Boots Alliance Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc and related companies with MarketBeat.com's FREE daily email newsletter.